Evidence map›Paper›PMID 41797638›Full record

ArticleHuman vaccines & immunotherapeutics2026

Genomic comparison reveals single-nucleotide polymorphic sites and attenuation-associated site combinations specific to Chinese live attenuated varicella-zoster virus vaccines.

Yuchan Zhang, Xuhua Duan, Yuanyuan Cai, Mingren Wang, Ziqiang Wang, Minghui Song, Tianyi Qiu, Xuanyi Wang, Hong Shao

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuchan ZhangNMPA Center for Innovation and Research in Regulatory Science, Shanghai Quality Inspection and Testing Center of Innovative Biological Products, Shanghai Institute for Drug Control, Shanghai, China.
Xuhua DuanNMPA Center for Innovation and Research in Regulatory Science, Shanghai Quality Inspection and Testing Center of Innovative Biological Products, Shanghai Institute for Drug Control, Shanghai, China.
Yuanyuan CaiNMPA Center for Innovation and Research in Regulatory Science, Shanghai Quality Inspection and Testing Center of Innovative Biological Products, Shanghai Institute for Drug Control, Shanghai, China.
Mingren WangNMPA Center for Innovation and Research in Regulatory Science, Shanghai Quality Inspection and Testing Center of Innovative Biological Products, Shanghai Institute for Drug Control, Shanghai, China.
Ziqiang WangNMPA Center for Innovation and Research in Regulatory Science, Shanghai Quality Inspection and Testing Center of Innovative Biological Products, Shanghai Institute for Drug Control, Shanghai, China.
Minghui SongNMPA Center for Innovation and Research in Regulatory Science, Shanghai Quality Inspection and Testing Center of Innovative Biological Products, Shanghai Institute for Drug Control, Shanghai, China.
Tianyi QiuInstitute of Clinical Science, Clinical Center of Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, China.
Xuanyi WangShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Hong ShaoNMPA Center for Innovation and Research in Regulatory Science, Shanghai Quality Inspection and Testing Center of Innovative Biological Products, Shanghai Institute for Drug Control, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The live-attenuated varicella-zoster virus (VZV) vaccine, mainly based on the Oka strain, is essential for the prevention and control of chickenpox (varicella). Although genomic profiles of internationally prevalent Oka vaccine strain (vOka)-derived preparations have been reported, the comprehensive single-nucleotide polymorphism (SNP) profiles of multiple commercially available Chinese vOka-derived vaccines are still lacking. We performed next-generation sequencing (NGS) on five Chinese-manufactured VZV vaccines, comparing genomic variations against the wild-type parental Oka (pOka) strain and internationally prevalent vaccine products. Notably, among 54 key SNPs distinguishing Chinese vaccines from the wild-type pOka strain, 4 novel China-specific SNPs were identified. What's more, we identified 6 near-fixed (the vaccine allele frequency >90%) non-synonymous SNPs that consistently co-occurred across all production batches, potentially impacting protein function through amino acid substitutions. Genetic heterogeneity across manufacturers revealed manufacturer-specific signatures, whereas consistent batch production underscored manufacturing stability. By systematically mapping SNPs in Chinese VZV vaccines, this study bridges a critical knowledge gap and provides essential insights into manufacturer-specific genomic signatures.

Indexed as

ChickenpoxChickenpox VaccineHerpesvirus 3, HumanPolymorphism, Single NucleotideChinaGenome, ViralHigh-Throughput Nucleotide SequencingHumansVaccines, AttenuatedChickenpox VaccineVaccines, Attenuatedbatch-to-batch consistencyChinese vOka-derived vaccinesgenetic heterogeneitysingle-nucleotide polymorphismVaricella-zoster virus

Identifiers

PMID41797638
PMCPMC12973467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.